Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic Solution
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dry Eye
Conditions
Dry Eye
Trial Timeline
Aug 28, 2021 → Mar 4, 2022
NCT ID
NCT05062330About Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic Solution
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic Solution is a phase 3 stage product being developed by Aldeyra Therapeutics for Dry Eye. The current trial status is completed. This product is registered under clinical trial identifier NCT05062330. Target conditions include Dry Eye.
What happened to similar drugs?
10 of 20 similar drugs in Dry Eye were approved
Approved (10) Terminated (2) Active (10)
🔄3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionSanten PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06493604 | Phase 3 | Completed |
| NCT06424444 | Phase 3 | Completed |
| NCT06389214 | Phase 3 | Completed |
| NCT05424549 | Phase 2 | Completed |
| NCT05234554 | Phase 3 | Completed |
| NCT05062330 | Phase 3 | Completed |
| NCT04971031 | Phase 2 | Completed |
| NCT04207736 | Phase 3 | Completed |
| NCT03709121 | Phase 1/2 | Completed |
| NCT03660878 | Phase 1/2 | Completed |
| NCT03494504 | Phase 3 | Completed |
| NCT03404115 | Phase 2 | Completed |
Competing Products
20 competing products in Dry Eye